An observational study in Emergency Medicine, sponsored by Mario Negri Institute for Pharmacological Research. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Mario Negri Institute for Pharmacological Research · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The peer-to-peer comparison means center-to-center comparison, which requires adjusting for possible differences among centers to be fair and convincing. The first step to reach this goal is to develop a predictive model that accurately estimates each patient's probability of being admitted, starting from clinical conditions and boundary variables. Such a model would make it possible to calculate, for each ED, the expected hospitalization rate; that is, the hospitalization rate that would have been observed if the ED had behaved like the average of the EDs that provided the data to build the model itself. Comparing the observed hospitalization rate in the single ED with the expected rate derived from the model provides a rigorous method of comparing the department with the average performance, taking into account the characteristics of the patients treated and the conditions under which the ED operated. In other words, the predictive model represents the benchmark against which each ED is evaluated.
Mario Negri Institute for Pharmacological Research is the lead sponsor of 161 studies on the registry; 38 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All adult patients who arrived at participating emergency departments between January 1, 2021 and December 31, 2023
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: no intervention
no intervention
Create two separate databases
To create two separate databases (one for each of the two subgroups considered) on all patients who presenteding to the participating EDs over a defined period, containing the information considered important to study both the propensity to hospitalize these patients and their 30-day mortality
Time frame: September 2024 - September 2025
Multivariable models
To develop two multivariable models that predict the probability that patients presenting to the ED with dyspnea (first model) or after a TLoC (second model) will be admitted to the hospital
Time frame: September 2025 - September 2026
Adjusted comparison
To provide the participating EDs with an adjusted comparison of the hospitalization rates for the patients with selected symptoms, to improve the quality of care.
Time frame: September 2025 - September 2026
Plan to share: Yes — eCREAM-UCI1 will join the MIP (Medical Informatics Platform), developed in the Human Brain Project (HBP), to federate clinical data. The MIP is an open-source, GDPR-compliant, privacy-aware platform, enabling remote and federated analyses from datasets physically distributed in various hospitals, research centers, and biobanks, without moving the data outside their original storage site to a central repository. Patient identification data will be deleted from the databases before these are uploaded to the MIP platform, and no pseudo-identifier will be available. See https://mip.ebrains.eu/ for more details on the MIP.
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mario Negri Institute for Pharmacological Research →